Vall d'Hebron Hospital

Newborns with Down syndrome, as they grow, face a higher risk of developing leukemia compared to those without the syndrome. An international team has sequenced the genes of more than 1.1 million cells from fetuses with and without Down syndrome, and it has discovered that the extra chromosome 21 they have alters the way DNA is packaged inside cells. According to the authors, whose research is published in Nature, this difference affects the regulation of certain genes and may contribute to the development of leukemia.

An international team of researchers has conducted a meta-analysis of 137 clinical trials involving nearly 90,000 people to assess the migraine efficacy of 17 available drugs. Their conclusions are that four drugs in the triptan group are more effective and cheaper than newer drugs such as gepants or lasmiditan, and that the efficacy of the latter is comparable to that of paracetamol and most anti-inflammatory drugs. The results are published in The BMJ.

The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended granting marketing authorisation in the European Union for Eurneffy (epinephrine), the first nasally administered medicine for the emergency treatment of allergic reactions. Anaphylaxis is the most severe form of allergic reaction that can occur within minutes of exposure to an allergen and can be life-threatening. Until now, treatment with epinephrine (also known as adrenaline) to reduce the anaphylactic reaction is done by intramuscular injection. 

People taking heartburn medications suffer more migraines and severe headaches, says a study published in Neurology: Clinical Practice. According to the authors, these observations are consistent with other studies that link migraine and headaches to the use of proton pump inhibitors (such as omeprazole), and the new study adds a correlation with the use of other types of antacids. The analysis is based on data from more than 11,800 adults between 1999 and 2004 in the United States. 

Researchers have found specific antibodies in the blood of patients years before they showed symptoms of multiple sclerosis. This group of antibodies was present in 10% of the 250 people who later developed the disease, and were part of a sample of over 10 million US military personnel. The finding could have potential for early detection of multiple sclerosis, says the research team in a paper published in Nature Medicine. 

In the year 2023, Science magazine has chosen the development and discovery that GLP-1 medications, agonists of the glucagon-like peptide-1, can mitigate health issues associated with obesity as the most important scientific breakthrough. Similarly, Nature magazine has selected biochemist Svetlana Mojsov, a key figure in the discovery of GLP-1, as one of the top ten scientists of the year. 

A study has analysed the association between ambient temperature and hospital mortality from respiratory diseases in the provinces of Madrid and Barcelona between 2006 and 2019. Their results indicate that high summer temperatures were responsible for 16% and 22.1% of all fatal hospitalisations for respiratory diseases in Madrid and Barcelona, respectively. According to the team, led by ISGlobal, "unless effective adaptation measures are taken in hospitals, global warming could exacerbate mortality in patients admitted for respiratory diseases during the summer period". The research is published in the journal The Lancet Regional Health - Europe.

A team of scientists led by the Catholic University of America in Washington has designed new artificial vectors based on viruses to improve gene therapy processes. The main novelty is that they are constructed from viruses that infect bacteria. Among other advantages, this would make it possible to avoid the possible memory of our defences against them and have a greater capacity. According to the authors, who publish their results in the journal Nature Communications, these nanoparticles "have the potential to transform gene therapies and personalised medicine".

A phase 2 clinical trial has analysed the safety and efficacy of adding immunotherapy to traditional chemotherapy to treat a subtype of acute lymphoblastic leukaemia in children under one year of age. This subtype of leukaemia, although rare in absolute terms, is the most common in children of this age, and its prognosis in this age group had not improved in recent years. The immunotherapy used, a bispecific antibody that binds to tumour cells on the one hand and T lymphocytes on the other, improved two-year survival from 66% to 93% in treated patients, according to The New England Journal of Medicine (NEJM).

Obesity is a growing public health problem for the entire planet. According to the 2023 Obesity Atlas published this week by the World Obesity Federation, 51% of the world's population will be overweight or obese (more than 4 billion people) by 2035, up from 38% today. At a briefing organised by SMC Spain ahead of World Obesity Day on 4 March, two experts discussed the role that drugs can play in combating a disease whose roots are social and linked to inequality.